Drug Profile
Repirinast
Alternative Names: BAY U 2372; BAY W 8199; MY 5116; RometLatest Information Update: 15 Feb 2008
Price :
$50
*
At a glance
- Originator Mitsubishi Chemical
- Developer Bayer; Mitsubishi Chemical; Mitsubishi Tanabe Pharma Corporation
- Class Antiallergics; Antiasthmatics; Quinolones
- Mechanism of Action Histamine release inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Asthma
Most Recent Events
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 24 Apr 2001 Mitsubishi-Tokyo Pharmaceuticals has reacquired exclusive Japanese marketing rights to repirinast from Nikken Chemical
- 16 Nov 1999 Tokyo Tanabe has been acquired by Mitsubishi Chemical